Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms.

NCT00590343 is registered in ClinicalTrials.gov with Louisiana State University Health Sciences Center in New Orleans as lead sponsor.

NCT NCT00590343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00590343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms.
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
October 31, 2010
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic neuroendocrine tumors